Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Frequency Therapeutics Inc (KRRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: KRRO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $101.83
1 Year Target Price $101.83
| 6 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.03% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 112.97M USD | Price to earnings Ratio - | 1Y Target Price 101.83 |
Price to earnings Ratio - | 1Y Target Price 101.83 | ||
Volume (30-day avg) 10 | Beta - | 52 Weeks Range 10.29 - 98.00 | Updated Date 06/30/2025 |
52 Weeks Range 10.29 - 98.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.42 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -981.18% |
Management Effectiveness
Return on Assets (TTM) -29.82% | Return on Equity (TTM) -60.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 42917904 | Price to Sales(TTM) 23.43 |
Enterprise Value 42917904 | Price to Sales(TTM) 23.43 | ||
Enterprise Value to Revenue 8.9 | Enterprise Value to EBITDA -5.6 | Shares Outstanding 9390490 | Shares Floating 4888127 |
Shares Outstanding 9390490 | Shares Floating 4888127 | ||
Percent Insiders 6.19 | Percent Institutions 104.41 |
Analyst Ratings
Rating 4 | Target Price 101.83 | Buy 4 | Strong Buy 6 |
Buy 4 | Strong Buy 6 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Frequency Therapeutics Inc
Company Overview
History and Background
Frequency Therapeutics, Inc. was founded in 2014. It is a biotechnology company focused on developing new therapies to activate progenitor cells within the body to restore healthy tissue.
Core Business Areas
- Hearing Loss Therapeutics: Developing novel regenerative therapies for hearing loss utilizing Progenitor Cell Activation (PCA) technology. Their lead product candidate is FX-322.
Leadership and Structure
David Lucchino is the Chief Executive Officer. The company has a board of directors and operates with functional departments typical of a biotechnology company, including research, development, clinical operations, and finance.
Top Products and Market Share
Key Offerings
- FX-322: FX-322 is Frequency Therapeutics' lead product candidate, an investigational locally administered drug designed to regenerate auditory hair cells within the cochlea for sensorineural hearing loss. As of December 2023, the company paused the development of FX-322 to focus on earlier stage assets. Competitors include companies developing gene therapies, cell therapies, and other small molecules for hearing loss (e.g., Decibel Therapeutics (DBTX)). Current FX-322 revenue is $0.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high risk and high reward. It is undergoing innovations in gene and cell therapies. The hearing loss therapeutics market is driven by the prevalence of hearing loss, an aging population, and technological advancements.
Positioning
Frequency Therapeutics aimed to be a leader in regenerative hearing loss therapies using their PCA platform. However, the clinical trial results led to them pausing development and seeking alternative approaches. Their positioning is now uncertain as they shift strategic direction.
Total Addressable Market (TAM)
The global hearing loss market is significant, estimated at billions of dollars annually. Frequency Therapeutics aimed to capture a portion of this market with FX-322. As they move into early assets, their position in the TAM needs to be re-evaluated.
Upturn SWOT Analysis
Strengths
- Novel PCA technology platform
- Experienced leadership team (prior to restructuring)
- Strong intellectual property portfolio (patents surrounding PCA platform)
Weaknesses
- Clinical trial failures of FX-322
- Uncertainty regarding future strategic direction
- Limited financial resources
- Dependence on a single technology platform
Opportunities
- Potential for strategic partnerships
- Development of new PCA-based therapies
- Exploration of other therapeutic areas for PCA technology
- Future funding opportunities
Threats
- Regulatory hurdles
- Competition from other companies developing hearing loss therapies
- Clinical trial failures of future product candidates
- Patent challenges
Competitors and Market Share
Key Competitors
- DBTX
Competitive Landscape
Frequency Therapeutics faces competition from companies pursuing various approaches to treating hearing loss. The change in strategic direction impacts the current competitive landscape. The competitive landscape is uncertain as it pauses development of FX-322.
Growth Trajectory and Initiatives
Historical Growth: The historical growth was centered around the advancement of FX-322. The growth trajectory has been significantly impacted due to the recent shift in the strategic direction.
Future Projections: Future projections are highly uncertain given the strategic shift. Analyst estimates are likely to be revised.
Recent Initiatives: Recent strategic initiatives include pausing development of FX-322 and focusing on earlier stage assets.
Summary
Frequency Therapeutics faces significant challenges after pausing development of their lead candidate, FX-322. The company is now focused on early assets. The future direction is uncertain, and its success depends on its ability to develop and commercialize future therapies. Poor financials and clinical trial results have greatly affected the company. Competitor success is a potential threat to the future growth of the company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Frequency Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Frequency Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2023-11-06 | CEO, President & Director Dr. Ram Aiyar MBA, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 112 | Website https://www.korrobio.com |
Full time employees 112 | Website https://www.korrobio.com | ||
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.